Charles E. Cooley

Array ( [id] => 16435720 [patent_doc_number] => 20200353045 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-12 [patent_title] => MONOMERIC CXCL121 PEPTIDE AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/745809 [patent_app_country] => US [patent_app_date] => 2020-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28299 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16745809 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16389650 [patent_doc_number] => 20200330591 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-22 [patent_title] => TREATMENT [patent_app_type] => utility [patent_app_number] => 16/729062 [patent_app_country] => US [patent_app_date] => 2019-12-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23972 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16729062 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16087007 [patent_doc_number] => 20200197490 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-25 [patent_title] => PHARMACEUTICAL COMPOSITIONS COMPRISING PEPTIDE VARIANTS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/719448 [patent_app_country] => US [patent_app_date] => 2019-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56509 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16719448 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15771381 [patent_doc_number] => 20200116708 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-16 [patent_title] => FATTY ACID BINDING PROTEIN 3 FOR THE ASSESSMENT OF ATRIAL FIBRILLATION (AF) [patent_app_type] => utility [patent_app_number] => 16/712084 [patent_app_country] => US [patent_app_date] => 2019-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11182 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16712084 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15898431 [patent_doc_number] => 20200148734 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-14 [patent_title] => Compositions and Methods for Improving Resistance to Breakage and Eggshell Strength [patent_app_type] => utility [patent_app_number] => 16/711821 [patent_app_country] => US [patent_app_date] => 2019-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5029 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16711821 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16238275 [patent_doc_number] => 20200255509 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-13 [patent_title] => THERAPEUTIC ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/708877 [patent_app_country] => US [patent_app_date] => 2019-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12725 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16708877 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17385633 [patent_doc_number] => 20220033485 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-03 [patent_title] => ANTI-IGF-I RECEPTOR HUMANIZED ANTIBODY [patent_app_type] => utility [patent_app_number] => 17/299383 [patent_app_country] => US [patent_app_date] => 2019-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18419 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 307 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17299383 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17503496 [patent_doc_number] => 20220096598 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-31 [patent_title] => FIBROBLAST GROWTH FACTOR 21 VARIANT, AND FUSION PROTEIN AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/310377 [patent_app_country] => US [patent_app_date] => 2019-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4129 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 92 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17310377 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17674145 [patent_doc_number] => 20220187312 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-16 [patent_title] => BIOMARKERS OF SUBCLINICAL ATHEROSCLEROSIS [patent_app_type] => utility [patent_app_number] => 17/290164 [patent_app_country] => US [patent_app_date] => 2019-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24311 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17290164 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17292269 [patent_doc_number] => 20210388108 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-16 [patent_title] => ANTIBODIES SPECIFIC FOR GLYCOSYLATED APOJ AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/287777 [patent_app_country] => US [patent_app_date] => 2019-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30150 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17287777 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17392493 [patent_doc_number] => 11241481 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-08 [patent_title] => Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases [patent_app_type] => utility [patent_app_number] => 16/600139 [patent_app_country] => US [patent_app_date] => 2019-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38392 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 145 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16600139 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15499065 [patent_doc_number] => 20200049721 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-13 [patent_title] => FASTING LEVELS OF GROWTH HORMONE AS A PREDICTIVE MARKER OF CARDIOVASCULAR RISK [patent_app_type] => utility [patent_app_number] => 16/598401 [patent_app_country] => US [patent_app_date] => 2019-10-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11079 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16598401 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17790520 [patent_doc_number] => 20220249611 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-11 [patent_title] => ENGINEERED FIBROBLAST GROWTH FACTOR VARIANTS AS RECEPTOR ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 17/283794 [patent_app_country] => US [patent_app_date] => 2019-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36743 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17283794 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17368333 [patent_doc_number] => 20220023385 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-27 [patent_title] => ENGINEERED FIBROBLAST GROWTH FACTOR VARIANTS COMBINED WITH ENGINEERED HEPATOCYTE GROWTH FACTOR VARIANTS FOR TREATMENT [patent_app_type] => utility [patent_app_number] => 17/283913 [patent_app_country] => US [patent_app_date] => 2019-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46077 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17283913 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17387057 [patent_doc_number] => 20220034909 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-03 [patent_title] => METHOD AND KIT FOR QUANTIFYING LIVER-TYPE FATTY ACID BINDING PROTEIN, METHOD AND KIT FOR TESTING FOR KIDNEY DISEASES, AND COMPANION DIAGNOSTIC DRUG [patent_app_type] => utility [patent_app_number] => 17/280602 [patent_app_country] => US [patent_app_date] => 2019-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9877 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17280602 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17067302 [patent_doc_number] => 20210269517 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-02 [patent_title] => METHOD OF TREATING WASTING DISORDERS [patent_app_type] => utility [patent_app_number] => 17/276611 [patent_app_country] => US [patent_app_date] => 2019-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19858 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17276611 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15646867 [patent_doc_number] => 20200085963 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-19 [patent_title] => CELL PENETRATING PROTEIN ADAPTOR MOLECULES AND THEIR APPLICATION IN RESEARCH AND MEDICINE [patent_app_type] => utility [patent_app_number] => 16/572066 [patent_app_country] => US [patent_app_date] => 2019-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5040 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16572066 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17007100 [patent_doc_number] => 20210238261 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-05 [patent_title] => MONOCLONAL ANTIBODY AGAINST S PROTEIN OF MERS-CORONAVIRUS, AND USE OF SAME [patent_app_type] => utility [patent_app_number] => 17/268503 [patent_app_country] => US [patent_app_date] => 2019-08-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7005 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17268503 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15524817 [patent_doc_number] => 20200054714 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-20 [patent_title] => Methods and Compositions for the Treatment of Metabolic Disorders and Diseases [patent_app_type] => utility [patent_app_number] => 16/533224 [patent_app_country] => US [patent_app_date] => 2019-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42001 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16533224 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15293571 [patent_doc_number] => 20190389921 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-26 [patent_title] => MUTANT FGF-21 PEPTIDE PEGYLATED CONJUGATES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/515544 [patent_app_country] => US [patent_app_date] => 2019-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30512 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 117 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16515544 [rel_patent_id] =>[rel_patent_doc_number] =>)